4.8 Article

A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis

Journal

JOURNAL OF HEPATOLOGY
Volume 59, Issue 3, Pages 474-481

Publisher

ELSEVIER
DOI: 10.1016/j.jhep.2013.04.036

Keywords

Cirrhosis; Ascites; Acute kidney injury; Kidney failure; Hepatorenal syndrome

Funding

  1. Fondo de Investigacion Sanitaria [FIS PI080126]
  2. Instituto de Salud Carlos III [FI10/00438]
  3. Instituto Reina Sofia de Investigacion Nefrologica
  4. Fundacion Banco de Bilbao-Vizcaya-Argentaria

Ask authors/readers for more resources

Background & Aims: The Acute Kidney Injury Network (AKIN) criteria are widely used in nephrology, but information on cirrhosis is limited. We aimed at evaluating the AKIN criteria and their relationship with the cause of kidney impairment and survival. Methods: We performed a prospective study of 375 consecutive patients hospitalized for complications of cirrhosis. One-hundred and seventy-seven (47%) patients fulfilled the criteria of Acute Kidney Injury (AKI) during hospitalization, the causes being hypovolemia, infections, hepatorenal syndrome (HRS), nephrotoxicity, and miscellaneous (62, 54, 32, 8, and 21 cases, respectively). Results: At diagnosis, most patients had AKI stage 1 (77%). Both the occurrence of AKI and its stage were associated with 3-month survival. However, survival difference between stages 2 and 3 was not statistically significant. Moreover, if stage 1 patients were categorized into 2 groups according to the level of serum creatinine used in the classical definition of kidney impairment (1.5 mg/dl), the two groups had a significantly different outcome. Combining AKIN criteria and maximum serum creatinine, 3 risk groups were identified: (A) patients with AKI stage 1 with peak creatinine 61.5 mg/dl; (B) patients with stage 1 with peak creatinine > 1.5 mg/dl; and (C) patients with stages 2-3 (survival 84%, 68%, and 36%, respectively; p < 0.001). Survival was independently related to the cause of kidney impairment, patients with HRS or infection-related having the worst prognosis. Conclusions: A classification that combines the AKIN criteria and classical criteria of kidney failure in cirrhosis provides a better risk stratification than AKIN criteria alone. The cause of impairment in kidney function is key in assessing prognosis in cirrhosis. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Gastroenterology & Hepatology

Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis

Gabriel Mezzano, Adria Juanola, Andres Cardenas, Esteban Mezey, James P. Hamilton, Elisa Pose, Isabel Graupera, Pere Gines, Elsa Sola, Ruben Hernaez

Summary: The study revealed high global prevalence and mortality rates of ACLF, with regional variations possibly explained by triggers/aetiology of CLD or grade.
Review Medicine, General & Internal

The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Tom H. Karlsen, Nick Sheron, Shira Zelber-Sagi, Patrizia Carrieri, Geoffrey Dusheiko, Elisabetta Bugianesi, Rachel Pryke, Sharon J. Hutchinson, Bruno Sangro, Natasha K. Martin, Michele Cecchini, Mae Ashworth Dirac, Annalisa Belloni, Miquel Serra-Burriel, Cyriel Y. Ponsioen, Brittney Sheena, Alienor Lerouge, Marion Devaux, Nick Scott, Margaret Hellard, Henkjan J. Verkade, Ekkehard Sturm, Giulio Marchesini, Hannele Yki-Jarvinen, Chris D. Byrne, Giovanni Targher, Aviad Tur-Sinai, Damon Barrett, Michael Ninburg, Tatjana Reic, Alison Taylor, Tim Rhodes, Carla Treloar, Claus Petersen, Christoph Schramm, Robert Flisiak, Marieta Y. Simonova, Albert Pares, Philip Johnson, Alessandro Cucchetti, Isabel Graupera, Christos Lionis, Elisa Pose, Nuria Fabrellas, Ann T. Ma, Juan M. Mendive, Vincenzo Mazzaferro, Harry Rutter, Helena Cortez-Pinto, Deirdre Kelly, Robyn Burton, Jeffrey Lazarus, Pere Gines, Maria Buti, Philip N. Newsome, Patrizia Burra, Michael P. Manns

LANCET (2022)

Review Gastroenterology & Hepatology

Long-term albumin treatment in patients with cirrhosis and ascites

Paolo Caraceni, Alastair O'Brien, Pere Gines

Summary: Long-term administration of albumin may be effective and safe for treating patients with cirrhosis and ascites, but further research is needed to determine the target population, optimal dose and frequency of treatment, stopping rules, and cost-effectiveness in different healthcare systems.

JOURNAL OF HEPATOLOGY (2022)

Editorial Material Medicine, General & Internal

Improving Outcome Prediction in Alcohol-Associated Hepatitis: Blood Urea Nitrogen and Albumin Help

Elisa Pose, Pere Gines

MAYO CLINIC PROCEEDINGS (2022)

Article Multidisciplinary Sciences

Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life

Marta Carol, Martina Perez-Guasch, Elsa Sola, Marta Cervera, Sara Martinez, Adria Juanola, Ann T. Ma, Emma Avitabile, Laura Napoleone, Elisa Pose, Isabel Graupera, Maria Honrubia, Marko Korenjak, Ferran Torres, Pere Gines, Nuria Fabrellas

Summary: Perceived stigma is common in patients with NAFLD regardless of disease stage, and is associated with impaired quality-of-life. This issue may affect the human and social rights of affected patients.

PLOS ONE (2022)

Correction Public, Environmental & Occupational Health

LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries (vol 22, 1385, 2022)

Isabel Graupera, Maja Thiele, Ann T. Ma, Miquel Serra-Burriel, Judit Pich, Nuria Fabrellas, Llorenc Caballeria, Robert J. de Knegt, Ivica Grgurevic, Mathias Reichert, Dominique Roulot, Joern M. Schattenberg, Juan M. Pericas, Paolo Angeli, Emmanuel A. Tsochatzis, Indra Neil Guha, Montserrat Garcia-Retortillo, Rosa M. Morillas, Rosario Hernandez, Jordi Hoyo, Matilde Fuentes, Anita Madir, Adria Juanola, Anna Soria, Marta Juan, Marta Carol, Alba Diaz, Soenke Detlefsen, Pere Toran, Guillem Pera, Celine Fournier, Anne Llorca, Phillip N. Newsome, Michael Manns, Harry J. de Koning, Feliu Serra-Burriel, Fernando Cucchietti, Anita Arslanow, Marko Korenjak, Laurens van Kleef, Josep Lluis Falco, Patrick S. Kamath, Tom H. Karlsen, Laurent Castera, Frank Lammert, Aleksander Krag, Pere Gines

BMC PUBLIC HEALTH (2023)

Review Gastroenterology & Hepatology

Organ dysfunction and failure in liver disease

Adria Juanola, Neha Tiwari, Cristina Sole, Danielle Adebayo, Florence Wong, Pere Gines

Summary: Acute-on-chronic liver failure (ACLF) is a complex syndrome associated with different organ failures in patients with chronic liver disease, mainly cirrhosis. Various definitions have been proposed, with differences in the severity of underlying liver disease, precipitating factors, and organs considered. Regardless of the definition, ACLF is characterized by hyperactive immune response, profound hemodynamic disturbances, and metabolic alterations leading to organ dysfunction. The triggers include bacterial infections, alcoholic hepatitis, gastrointestinal bleeding, and hepatitis B virus flare. Prompt recognition and treatment of the trigger event, as well as specific organ support, are crucial to improve short-term mortality. Liver transplantation may be considered in carefully selected patients.

LIVER INTERNATIONAL (2023)

Meeting Abstract Gastroenterology & Hepatology

NOVEL BIOMARKERS FOR PROGNOSIS ASSESSMENT OF PATIENTS WITH DECOMPENSATED CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Adria Juanola, Ann T. Ma, Koos De Wit, Kohilan Gananandan, Olivier Roux, Giacomo Zaccherini, Cesar Jimenez, Marta Tonon, Cristina Sole, Clara Villaseca, Frank Erhard Uschner, Isabel Graupera, Elisa Pose, Elsa Sola, Ulrich Beuers, Rajeshwar P. Mookerjee, Claire Francoz, Victor Vargas, Salvatore Piano, Sonia Alonso, Jonel Trebicka, Wim Laleman, Sumeet K. Asrani, German Soriano Pastor, Miquel Serra-Burriel, Manuel Morales-Ruiz, Ferran Torres, Andrew S. Allegretti, Aleksander Krag, Paolo Caraceni, Hugh Watson, Juan G. Abraldes, Patrick S. Kamath, Pere Gines, Ruben Hernaez

HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis

Jesus Rivera-Esteban, Ramiro Manzano-Nunez, Teresa Broquetas, Isabel Serra-Matamala, Octavi Bassegoda, Agnes Soriano-Varela, Gemma Espin, Joaquin Castillo, Juan Banares, Jose A. Carrion, Pere Gines, Isabel Graupera, Juan M. Pericas

Summary: The study evaluated the impact of the COVID-19 pandemic on outcomes of NAFLD cirrhosis patients, finding that although metabolic control worsened during the pandemic, it was mainly due to non-liver causes, namely COVID-19 itself.

JHEP REPORTS (2022)

Article Gastroenterology & Hepatology

High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study

Octavi Bassegoda, Jesus Rivera-Esteban, Isabel Serra, Rosa Morillas, Teresa Broquetas, Mercedes Vergara, Adria Rodriguez, Carles Aracil, Silvia Viroles, Jose A. Carrion, Albert Pardo, Sergio Rodriguez-Tajes, Miquel Serra-Burriel, Juan M. Pericas, Salvador Augustin, Pere Gines, Isabel Graupera

Summary: The aim of this study was to assess the incidence and risk factors of acute decompensation of cirrhosis, hepatocellular carcinoma, and extrahepatic cancers in patients with compensated cirrhosis due to nonalcoholic fatty liver disease. The results showed that these patients are at high risk of severe liver complications, such as the development of acute decompensation, in a relative short follow-up time, and they are also at high risk of hepatic and extrahepatic cancers.

HEPATOLOGY COMMUNICATIONS (2022)

Meeting Abstract Gastroenterology & Hepatology

Natural history of hepatic steatosis associated to metabolic syndrome. Longitudinal study with 5 years of follow-up

Marta Cervera, Marta Carol, Ana Belen Rubio, Martina Perez, Carlota Riba, Rosario Hernandez, Ann Ma, Emma Avitabile, Anna Soria, Octavi Bassegoda, Sara Martinez, Jordi Gratacos-Gines, Adria Juanola, Laura Napoleone, Elisa Pose, Isabel Graupera, Pere Gines, Nuria Fabrellas

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression

Maria Del Barrio Azaceta, Paula Iruzubieta, Rocio Aller de la Fuente, Jesus Maria Banales, Alvaro Santos-Laso, Jose Luis Calleja Panero, Luis Ibanez, Maria Teresa Arias Loste, Manuel Romero Gomez, Carmelo Garcia-Monzon, Judith Gomez-Camarero, Pere Gines, Rosa M. Morillas, Juan Manuel Pericas, Patricia Aspichueta, Rosa Martin-Mateos, Rocio Gallego-Duran, Mercedes De La Torre Sanchez, Desamparados Escudero-Garcia, Vanesa Bernal Monterde, Salvador Benlloch, Juan Turnes, Javier Crespo

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors

Maria Del Barrio Azaceta, Paula Iruzubieta, Rocio Aller De La Fuente, Jesus Maria Banales, Alvaro Santos-Laso, Jose Luis Calleja Panero, Luis Ibanez, Maria Teresa Arias Loste, Manuel Romero Gomez, Carmelo Garcia-Monzon, Judith Gomez-Camarero, Pere Gines, Rosa M. Morillas, Juan Manuel Pericas, Patricia Aspichueta, Rosa Martin-Mateos, Rocio Gallego-Duran, Mercedes De La Torre Sanchez, Desamparados Escudero-Garcia, Vanesa Bernal Monterde, Salvador Benlloch, Juan Turnes, Javier Crespo

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

The proteomic analysis of hepatic stellate cell differentiation from iPSCs identifies RORalpha as an antifibrogenic target

Raquel A. Martinez Garcia de la Torre, Julia Vallverdu, Silvia Arino Mons, Beatriz Aguilar-Bravo, Mikel Azkargorta, Felix Elortza, Laura Zanatto, Paula Cantallops Vila, Juanjo Lozano, Benedicte Antoine, Isabel Graupera, Pere Gines, Pau Sancho-Bru

JOURNAL OF HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

Elisa Pose, Elsa Sola, Juan J. Lozano, Adria Juanola, Julia Sidorova, Giacomo Zaccherini, Koos de Wit, Frank Uschner, Marta Tonon, Konstantin Kazankow, Cesar Jimenez, Daniela Campion, Laura Napoleone, Ann T. Ma, Marta Carol, Manuel Morales-Ruiz, Carlo Alessandria, Ulrich Beuers, Paolo Caraceni, Claire Francoz, Francois Durand, Rajeshwar P. Mookerjee, Jonel Trebicka, Victor Vargas, Salvatore Piano, Hugh Watson, Juan G. Abraldes, Patrick S. Kamath, Mark M. Davis, Pere Gines

Summary: This study investigated the effects of simvastatin and rifaximin on plasma metabolites in patients with decompensated cirrhosis and ACLF, identifying specific metabolic changes associated with ACLF and noting alterations in key pathways with treatment. The findings suggest a potential for targeted therapies in cirrhosis to prevent ACLF development.

HEPATOLOGY COMMUNICATIONS (2022)

No Data Available